BioCardia (BCDA) Competitors $2.02 -0.02 (-0.78%) As of 02:37 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BCDA vs. GBIO, PEPG, SNTI, AADI, ACRV, EGRX, RENB, PYRGF, LVTX, and MDCXShould you be buying BioCardia stock or one of its competitors? The main competitors of BioCardia include Generation Bio (GBIO), PepGen (PEPG), Senti Biosciences (SNTI), Aadi Bioscience (AADI), Acrivon Therapeutics (ACRV), Eagle Pharmaceuticals (EGRX), Renovaro (RENB), PyroGenesis Canada (PYRGF), LAVA Therapeutics (LVTX), and Medicus Pharma (MDCX). These companies are all part of the "pharmaceutical products" industry. BioCardia vs. Its Competitors Generation Bio PepGen Senti Biosciences Aadi Bioscience Acrivon Therapeutics Eagle Pharmaceuticals Renovaro PyroGenesis Canada LAVA Therapeutics Medicus Pharma BioCardia (NASDAQ:BCDA) and Generation Bio (NASDAQ:GBIO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability. Which has more risk and volatility, BCDA or GBIO? BioCardia has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500. Comparatively, Generation Bio has a beta of 2.48, meaning that its stock price is 148% more volatile than the S&P 500. Does the media refer more to BCDA or GBIO? In the previous week, BioCardia had 2 more articles in the media than Generation Bio. MarketBeat recorded 3 mentions for BioCardia and 1 mentions for Generation Bio. BioCardia's average media sentiment score of -1.00 equaled Generation Bio'saverage media sentiment score. Company Overall Sentiment BioCardia Negative Generation Bio Negative Do analysts prefer BCDA or GBIO? BioCardia currently has a consensus price target of $25.00, suggesting a potential upside of 1,135.18%. Generation Bio has a consensus price target of $10.67, suggesting a potential upside of 85.51%. Given BioCardia's stronger consensus rating and higher possible upside, analysts plainly believe BioCardia is more favorable than Generation Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioCardia 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Generation Bio 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Do institutionals & insiders hold more shares of BCDA or GBIO? 20.6% of BioCardia shares are held by institutional investors. Comparatively, 95.2% of Generation Bio shares are held by institutional investors. 20.0% of BioCardia shares are held by insiders. Comparatively, 21.8% of Generation Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Is BCDA or GBIO more profitable? BioCardia has a net margin of 0.00% compared to Generation Bio's net margin of -341.12%. Generation Bio's return on equity of -91.07% beat BioCardia's return on equity.Company Net Margins Return on Equity Return on Assets BioCardiaN/A -19,117.42% -246.92% Generation Bio -341.12%-91.07%-33.65% Which has higher valuation & earnings, BCDA or GBIO? BioCardia has higher earnings, but lower revenue than Generation Bio. BioCardia is trading at a lower price-to-earnings ratio than Generation Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioCardiaN/AN/A-$7.95M-$1.85-1.09Generation Bio$21.23M1.82-$131.67M-$10.82-0.53 SummaryGeneration Bio beats BioCardia on 8 of the 15 factors compared between the two stocks. Get BioCardia News Delivered to You Automatically Sign up to receive the latest news and ratings for BCDA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BCDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCDA vs. The Competition Export to ExcelMetricBioCardiaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.72M$3.10B$5.75B$9.87BDividend YieldN/A2.28%6.66%4.49%P/E Ratio-1.0920.8082.8226.56Price / SalesN/A372.93500.42162.62Price / CashN/A43.5325.7028.92Price / Book-6.138.0510.796.50Net Income-$7.95M-$53.35M$3.28B$266.21M7 Day Performance3.27%-0.80%-0.25%-1.06%1 Month Performance3.27%6.16%6.71%3.51%1 Year Performance-21.55%11.03%49.66%23.94% BioCardia Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCDABioCardia2.607 of 5 stars$2.02-0.8%$25.00+1,135.2%-28.9%$11.72MN/A-1.0940News CoverageNegative NewsShort Interest ↑GBIOGeneration Bio2.6868 of 5 stars$6.10-5.4%$10.67+74.9%-75.5%$43.44M$21.23M-0.56150Negative NewsShort Interest ↑PEPGPepGen2.1049 of 5 stars$1.31-0.8%$7.67+485.2%-87.0%$43.30MN/A-0.4430Gap UpSNTISenti Biosciences1.7513 of 5 stars$1.59-3.3%$8.50+434.6%-45.1%$43.03M$2.56M-0.184AADIAadi BioscienceN/A$1.74+5.5%$1.75+0.6%+4.6%$42.97M$25.07M-0.7640ACRVAcrivon Therapeutics2.4362 of 5 stars$1.33-2.2%$17.57+1,221.2%-84.1%$42.78MN/A-0.5958EGRXEagle Pharmaceuticals1.8052 of 5 stars$3.19flatN/A-33.6%$41.43M$257.55M0.00100Gap DownRENBRenovaro0.73 of 5 stars$0.23-4.2%N/A-57.5%$41.14MN/A-0.3020News CoverageShort Interest ↑PYRGFPyroGenesis Canada0.156 of 5 stars$0.22-3.9%N/A-64.8%$40.38M$9.14M-3.5990News CoverageNegative NewsShort Interest ↑Gap DownLVTXLAVA Therapeutics1.2797 of 5 stars$1.51-1.3%$2.69+77.8%+0.0%$40.25M$11.98M-1.4460Short Interest ↑MDCXMedicus Pharma1.7718 of 5 stars$2.17-2.3%$23.50+982.9%N/A$39.55MN/A-1.62N/AAnalyst Forecast Related Companies and Tools Related Companies GBIO Alternatives PEPG Alternatives SNTI Alternatives AADI Alternatives ACRV Alternatives EGRX Alternatives RENB Alternatives PYRGF Alternatives LVTX Alternatives MDCX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BCDA) was last updated on 9/4/2025 by MarketBeat.com Staff From Our Partners“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThis Massive Market is Ripe for Disruption by this NasdaqFanatics Hit $31B. This Nasdaq Company Is Building the Next Wave Fanatics built a merch empire by owning th...i2i Marketing Group, LLC | Sponsored“Shadow Group” in Washington, DC Could Crash MarketNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredDid you spot this in the Oval Office last week?When Tim Cook stood in the Oval Office last week, all eyes were on the "unique 24K gold gift" he presented to ...InvestorPlace | SponsoredTrump’s national nightmare is hereThe headlines are shocking: Washington has taken a $10 billion stake in one of America’s biggest chipmakers — ...Porter & Company | SponsoredWall Street Legend Names #1 ‘Hidden’ AI Stock50-year Wall Street legend says to forget NVDA. For the biggest potential gains, it's time to move your money ...Chaikin Analytics | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioCardia, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioCardia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
